Cite
HARVARD Citation
Kim, Y. et al. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet oncology. 19 (9), pp. 1192-1204. [Online].